BIA reaction to Queen’s speech

​​​​​​​Steve Bates OBE, CEO of the BIA said: “It’s great to hear the Government recognises the enormous contribution of the UK life sciences sector to the wider UK economy, which was highlighted at numerous points in today’s Queen’s speech.

CEO Update|Monday 14 October

The weather may have caused maximum disruption in Japan this week, but not for biotech.

BIA meets FIRM in Japan

At a ceremony last Friday at BIO Japan in Yokohama, the BIA and the Japanese Forum for Innovative Regenerative Medicine (FIRM) exchanged directories of our members operating in the Cell and Gene Therapy space. This exciting new business tool springs from a partnership that was cemented with the signing of a Memorandum of Understanding between the BIA and FIRM earlier in the year. On our side, the work is led by the Cell and Gene Therapy Advisory Committee (CGTAC).

BIA exchanges member directories with Japanese leader in regenerative medicine

The UK Bioindustry Association (BIA) has exchanged member directories with The Forum for Innovative Regenerative Medicine (FIRM).

BioBeat19: Accelerating cell and gene therapy hosted by BioBeat

The cell and gene therapy sector is expanding fast, bringing undreamt of opportunities for scientists, entrepreneurs, innovators and investors. I hope you will join us for BioBeat19: Accelerating cell and gene therapy hosted by BioBeat in conjunction with GSK and Stevenage Bioscience Catalyst at GSK Stevenage.

Overcoming the barriers to cell and gene therapies

The last decade has seen significant scientific developments in cell therapies, gene therapies and tissue engineered products, collectively described as ATMPs (Advanced Therapy Medicinal Products). The impact of such treatments could be transformational. As such, we believe it is crucially important to support the sector as it navigates the complex clinical, regulatory, manufacturing, and pricing environments in which it operates.

MedAnnex begins cell line development at FUJIFILM Diosynth

Edinburgh-based biotechnology company MedAnnex today announced that cell line development for the generation of its anti-Annexin A1 antibodies is under way, at FUJIFILM Diosynth Biotechnologies’ (Fujifilm) Billingham, UK site.

Cellexus go global with new distribution network

Biotech company, Cellexus International Ltd, have increased their distributor network to bring their CellMaker bioreactor range to a global market.

BIA respond to written ministerial statement on continuity of supply in a no-deal Brexit

Steve Bates OBE, Chief Executive of the BIA said: “I ask all companies that are seeking to use the Government procured supply routes to import and export medicines in the event of a no-deal to register their interest immediately. This is best done by replying to the communication from the Department of Health yesterday. This is a key step to enable companies to book and purchase government procured ferry space -as details of it emerge- in the weeks ahead.  

CEO Update|Monday 07 October 2019

With weeks to go until the 31 Oct Brexit deadline, this week Prime Minister Boris Johnson outlined his latest Brexit proposals, focussed on alternative solutions to the Irish border question.